ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 126 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,666,000 | -14.2% | 227,500 | 0.0% | 0.03% | -17.5% |
| Q1 2019 | $3,106,000 | +33.2% | 227,500 | 0.0% | 0.04% | +11.1% |
| Q4 2018 | $2,332,000 | -38.4% | 227,500 | 0.0% | 0.04% | -28.0% |
| Q3 2018 | $3,788,000 | +10.2% | 227,500 | +4.6% | 0.05% | -7.4% |
| Q2 2018 | $3,437,000 | +53.8% | 217,500 | +23.6% | 0.05% | +42.1% |
| Q1 2018 | $2,235,000 | +93.3% | 176,000 | +74.3% | 0.04% | +90.0% |
| Q4 2017 | $1,156,000 | -19.3% | 101,000 | -13.7% | 0.02% | -20.0% |
| Q3 2017 | $1,433,000 | +6.9% | 117,000 | 0.0% | 0.02% | 0.0% |
| Q2 2017 | $1,340,000 | -40.9% | 117,000 | +7.3% | 0.02% | -43.2% |
| Q1 2017 | $2,267,000 | +172.5% | 109,000 | +172.5% | 0.04% | +131.6% |
| Q4 2016 | $832,000 | -36.5% | 40,000 | 0.0% | 0.02% | -40.6% |
| Q3 2016 | $1,311,000 | -38.1% | 40,000 | 0.0% | 0.03% | -27.3% |
| Q2 2015 | $2,119,000 | – | 40,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 2,942,130 | $40,160,000 | 10.45% |
| Foresite Capital Management II, LLC | 1,586,220 | $21,652,000 | 9.78% |
| DAFNA Capital Management LLC | 571,013 | $7,794,000 | 3.36% |
| Redmile Group, LLC | 8,244,896 | $112,543,000 | 3.29% |
| Lion Point Capital, LP | 1,271,500 | $17,355,000 | 1.57% |
| Palo Alto Investors LP | 1,861,630 | $25,411,000 | 1.06% |
| SAMLYN CAPITAL, LLC | 3,185,983 | $43,488,000 | 1.03% |
| Bellevue Group AG | 1,286,748 | $17,564,000 | 0.97% |
| BB BIOTECH AG | 2,766,008 | $37,756,000 | 0.95% |
| Rock Springs Capital Management LP | 1,560,000 | $21,294,000 | 0.82% |